Hepion Pharmaceuticals (HEPA) Competitors $0.62 -0.06 (-8.82%) (As of 10:20 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends HEPA vs. CLSN, CGTX, TNXP, FNCH, PRPH, APRE, NNVC, CARA, CVKD, and MRNSShould you be buying Hepion Pharmaceuticals stock or one of its competitors? The main competitors of Hepion Pharmaceuticals include Imunon (CLSN), Cognition Therapeutics (CGTX), Tonix Pharmaceuticals (TNXP), Finch Therapeutics Group (FNCH), ProPhase Labs (PRPH), Aprea Therapeutics (APRE), NanoViricides (NNVC), Cara Therapeutics (CARA), Cadrenal Therapeutics (CVKD), and Marinus Pharmaceuticals (MRNS). These companies are all part of the "medical" sector. Hepion Pharmaceuticals vs. Imunon Cognition Therapeutics Tonix Pharmaceuticals Finch Therapeutics Group ProPhase Labs Aprea Therapeutics NanoViricides Cara Therapeutics Cadrenal Therapeutics Marinus Pharmaceuticals Hepion Pharmaceuticals (NASDAQ:HEPA) and Imunon (NASDAQ:CLSN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment, community ranking and analyst recommendations. Is HEPA or CLSN more profitable? Hepion Pharmaceuticals has a net margin of 0.00% compared to Imunon's net margin of -5,229.80%. Imunon's return on equity of -50.18% beat Hepion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Hepion PharmaceuticalsN/A -512.95% -169.89% Imunon -5,229.80%-50.18%-36.94% Do analysts rate HEPA or CLSN? Given Imunon's higher probable upside, analysts plainly believe Imunon is more favorable than Hepion Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hepion Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Imunon 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor HEPA or CLSN? In the previous week, Hepion Pharmaceuticals had 3 more articles in the media than Imunon. MarketBeat recorded 3 mentions for Hepion Pharmaceuticals and 0 mentions for Imunon. Hepion Pharmaceuticals' average media sentiment score of 0.22 beat Imunon's score of 0.00 indicating that Hepion Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Hepion Pharmaceuticals Neutral Imunon Neutral Which has preferable valuation and earnings, HEPA or CLSN? Imunon has higher revenue and earnings than Hepion Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHepion PharmaceuticalsN/AN/A-$48.93M-$4.38-0.14Imunon$500K0.00-$20.77MN/AN/A Does the MarketBeat Community favor HEPA or CLSN? Imunon received 366 more outperform votes than Hepion Pharmaceuticals when rated by MarketBeat users. However, 67.74% of users gave Hepion Pharmaceuticals an outperform vote while only 57.42% of users gave Imunon an outperform vote. CompanyUnderperformOutperformHepion PharmaceuticalsOutperform Votes2167.74% Underperform Votes1032.26% ImunonOutperform Votes38757.42% Underperform Votes28742.58% Which has more volatility & risk, HEPA or CLSN? Hepion Pharmaceuticals has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Imunon has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500. Do institutionals & insiders have more ownership in HEPA or CLSN? 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. Comparatively, 13.0% of Imunon shares are held by institutional investors. 2.0% of Hepion Pharmaceuticals shares are held by insiders. Comparatively, 4.7% of Imunon shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryImunon beats Hepion Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Ad Behind the Markets❗ RSVP please!Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.Just click here and secure your spot! Get Hepion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HEPA vs. The Competition Export to ExcelMetricHepion PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.32M$6.31B$4.81B$8.64BDividend YieldN/A8.11%7.42%4.07%P/E Ratio-0.149.26116.5617.08Price / SalesN/A360.921,320.3585.65Price / CashN/A50.7536.8135.17Price / Book0.489.826.426.06Net Income-$48.93M$149.47M$113.01M$223.16M7 Day Performance-7.19%-4.43%111.78%0.52%1 Month Performance-24.21%-3.98%116.39%5.13%1 Year Performance-79.87%30.29%155.25%25.67% Hepion Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HEPAHepion Pharmaceuticals0.4996 of 5 stars$0.62-8.8%N/A-77.9%$4.32MN/A-0.1420Gap DownCLSNImunonN/AN/AN/AN/A$13.91M$500,000.000.0027Analyst ForecastCGTXCognition Therapeutics2.6564 of 5 stars$0.46-9.8%N/A-55.2%$18.51MN/A-0.4820Analyst ForecastGap UpTNXPTonix Pharmaceuticals3.0298 of 5 stars$0.13-7.1%N/A-99.1%$17.99M$12.46M0.00103Earnings ReportFNCHFinch Therapeutics GroupN/A$11.20-6.7%N/A+194.7%$17.99M$110,000.00-1.27190Gap DownPRPHProPhase Labs3.3317 of 5 stars$0.75flatN/A-83.0%$17.91M$17.97M-0.60130Short Interest ↓Gap DownHigh Trading VolumeAPREAprea Therapeutics3.3728 of 5 stars$3.25-3.0%N/A-16.7%$17.65M$580,000.00-1.167Analyst ForecastGap DownNNVCNanoViricidesN/A$1.23-8.2%N/A+10.8%$17.16MN/A-1.7620Gap UpCARACara Therapeutics4.0016 of 5 stars$0.31-6.0%N/A-71.7%$17.06M$20.97M-0.1555News CoverageGap DownCVKDCadrenal Therapeutics1.9784 of 5 stars$15.66-5.5%N/AN/A$16.73MN/A-2.344Gap UpMRNSMarinus Pharmaceuticals4.4416 of 5 stars$0.30-3.2%N/A-95.1%$16.66M$30.99M-0.12110Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies CLSN Alternatives CGTX Alternatives TNXP Alternatives FNCH Alternatives PRPH Alternatives APRE Alternatives NNVC Alternatives CARA Alternatives CVKD Alternatives MRNS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HEPA) was last updated on 11/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredFREE investing Class TOMORROW + 2 FREE BonusesOver the last 37 years on Wall Street, I've developed a unique investing strategy that allows me to find stock...Unstoppable Prosperity | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored🗓️ My First LIVE Event in 5 Years!Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
